SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " pharmaceutical " 252 found 🔀 AI-powered Shuffle
CEO transition puts pharma business in the driver’s seat at Aptar
The company that turned the condiment world upside-down is now turning drug delivery on its nose at the same time it elevates its pharmaceutical leader to CEO.
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-term
Stada Hunts for Major Consumer Health Deal After Record Profit
German pharmaceutical firm Stada said it’s ready to make a major consumer health acquisition as it books record profit and transitions to new ownership.
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, England & BOSTON, March 17, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent corporate updates.
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Scientists Discover Where Drug Residues End Up Inside Crops
Scientists discovered that crops exposed to trace pharmaceuticals in recycled water mostly stash the compounds in their leaves—not the parts we usually eat.
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended Decembe
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition Top $250,000 Regeneron Science Talent Search Winner Named Regeneron and Society for Science announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), a program of Society for Science. TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. and Societ
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (P
Health Care Roundup: Market Talk
Find insight on Bayer, Neuren Pharmaceuticals , and more in the latest Market Talks covering Health Care.
The science of structures: FSU chemist synthesizes complex molecule with potential for medicine, pharmaceutical applications
A Florida State University chemist has developed a method to rapidly assemble significantly complex natural molecules with potential in biomedical
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta, February 26, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress.
San Diego Festival of Science and Engineering brings industry leaders to Petco Park
Exhibitors include Ballet Folklorico Moncayo, Children’s Museum of Discovery and the U.S. Navy, plus major pharmaceutical companies like Bristol Myers Squibb and Genentech among others.
AbbVie to invest $380 million to expand US manufacturing in Illinois
AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.
Girding against Keytruda cliff, Merck splits oncology into standalone business unit
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines by splitting its core pharmaceutical business in two.
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wave
Exclusive | Merck Creates Separate Cancer Business as Sales Pressure Looms
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
PRET for impact: Advancing pandemic preparedness in the Democratic People’s Republic of Korea
IN THE SPOTLIGHT PRET for impact: Advancing pandemic preparedness in the Democratic People’s Republic of KoreaThe Democratic People’s Republic of Korea (DPR Korea) is making significant progress in strengthening pandemic preparedness, with dedicated support from the WHO South‑East Asia Regional Office (SEARO) and the Pandemic Influenza Preparedness (PIP) Partnership Contribution (PC).Aligned with the WHO Global Influenza Strategy and the Pandemic Influenza Preparedness (PIP) Framework Partnership Contribution High‑Level Implementation Plan III (2024–2030), the country is strengthening its capacity to prepare for and respond to influenza and other respiratory threats. In early 2025, a core team from the Ministry of Public Health of the Democratic People’s Republic of Korea (DPRK) participated in a two‑day virtual workshop, which included a mini‑simulation exercise. The workshop was organized by WHO SEARO in collaboration with the Preparedness and Resilience for Emerging Threats (PRET) Secretariat at WHO headquarters and the WHO Country Office for the DPRK. Read more A REGIONAL CONSULTATION GUIDES WHO SEARO IN DEVELOPING A ROADMAP FOR IMPLEMENTING THE PREPPAREDNESS AND RESILIENCE FOR EMERGING THREATS (PRET) INITIATIVE BASED RESPIRATORY PATHOGEN PANDEMIC PREPAREDNESSInfluenza and other respiratory pathogens with pandemic potential continue to pose major public health risks globally. To strengthen regional preparedness and response, Member States of the WHO South‑East Asia Region (SEAR) convened in Colombo, Sri Lanka, to review and provide input on the draft Roadmap and Action Framework for Broad Respiratory Pathogen Pandemic Planning (2026–2031). Supported through the Pandemic Influenza Preparedness (PIP) Partnership Contribution (PC) funds, the proposed roadmap aims to advance robust, integrated preparedness and response capacities for influenza and other respiratory threats across SEAR. This work is aligned with the Preparedness and Resilience for Emerging Threats (PRET) initiative and the SEAR Strategic Roadmap on Health Security and Health System Resilience for Emergencies Read moreSRI LANKA’S USE OF ANTIVIRALS TO REDUCE THE SEASONAL INFLUENZA BURDEN Sri Lanka is strengthening its influenza response by placing greater emphasis on rapid testing, timely treatment, and integration with maternal health services. With support from WHO, the country is building a stronger evidence base on the burden of influenza and the value of vaccination, advancing a holistic approach to protect vulnerable populations and enhance pandemic preparedness. To reduce hospitalizations and deaths from seasonal influenza, Sri Lanka is taking proactive steps to expand access to rapid diagnostic testing and ensure prompt initiation of treatment. National clinical guidelines recommend the use of oseltamivir for individuals at high risk of complications, helping prevent severe illness and shorten the duration of infection. This strategy not only saves lives but also supports local pharmaceutical production, contributing to a reliable supply of antivirals for both seasonal outbreaks and future pandemics.Read moreBHUTAN BOOSTS PANDEMIC INFLUENZA READINESS WITH PANDEMIC INFLUENZA PREPAREDNESS FRAMEWORK PARTNERSHIP CONTRIBUTION SUPPORTED TRAINING AND SIMULATIONSOriginally developed in 2012, the National Influenza Pandemic Preparedness and Response Plan (NIPPRP) has long served as Bhutan’s central framework for managing influenza threats. In 2024, the plan underwent a comprehensive update to reflect evolving global and regional guidance, lessons learned from the COVID‑19 pandemic, and new capacities developed under the PIP Framework. The revised NIPPRP is now more clearly aligned with Bhutan’s broader emergency and disaster risk management structures, ensuring a coordinated, whole‑of‑government approach to pandemic response. As part of efforts to strengthen national pandemic preparedness, Bhutan conducted three national‑level training sessions followed by simulation exercises on influenza pandemic preparedness and response at five sentinel hospitals between April and May 2025, with support from the PIP Partnership Contribution (PC). These activities brought together more than 140 health professionals and key partners from across the country, with a focus on operationalizing the updated NIPPRP and enhancing readiness at key frontline facilities. Read moreSTRENGTHENING INFLUENZA SURVEILLANCE: WHO BRINGS TOGETHER INFLUENZA EXPERTS FROM SOUTH-EAST ASIA AND WESTERN PACIFIC REGIONSThe World Health Organization (WHO) convened the 18th Bi‑regional Meeting of National Influenza Centres (NICs) and Influenza Surveillance for the WHO South‑East Asia and Western Pacific Regions from 9–11 September 2025. Hosted by the WHO South‑East Asia Regional Office (SEARO), the meeting brought together representatives from Member States, Territories, and Areas across both regions, alongside experts from the WHO Collaborating Centres for Reference and Research on Influenza in Australia and Japan, the WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals in the United States, quadripartite partners (WOAH and FAO), and other technical counterparts. The consultation provided a platform to review progress, share experiences, and outline priorities for strengthening influenza and respiratory pathogen surveillance across the two WHO regions.Read moreNETWORKS AND TECHNICAL PARTNERSHIPSSTRENGTHENING PANDEMIC READINES: SOUTH-EAST ASIA ADVANCES UNITY STUDIES UNDER THE PANDEMIC INFLUENZA PREPAREDNESS INITIATIVEThe WHO Global Influenza Surveillance and Response System (GISRS) Investigations & Studies initiative, also known as Unity Studies, provides a standardized, globally coordinated framework to support these efforts. Originally developed for influenza and adapted during COVID-19, Unity Studies enable countries to conduct rapid, nationally led investigations and studies to assess transmissibility, severity, susceptibility, and intervention effectiveness. To better prepare for future influenza pandemics, WHO has recently launched a network of sites which will be ready to conduct these investigations and studies rapidly in the event of a pandemic, or epidemic of an emerging or re-emerging respiratory pathogen. The WHO South-East Asia Region now hosts six sites of WHO GISRS Unity Studies across the five countries including Sri Lanka, strengthening regional capacity for early pandemic investigations. From 13–16 July 2025 in Colombo, the Global Public Health Summit offered an opportunity to advance this agenda. Read moreSTRENGTHENING PANDEMIC PREPAREDNESS THROUGH UNITY STUDIES: REAL-WORLD APPLICATIONS FROM INDIA IN WHO’S SOUTH-EAST ASIA REGION As countries continue to strengthen their pandemic preparedness through investments in resilient health systems during the interpandemic period, the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS) Investigations & Studies Global Initiative, Global Initiative, commonly known as Unity Studies, remains a vital framework for respiratory pathogen pandemic preparedness. These standardized epidemiological protocols enable countries to rapidly generate high‑quality data on transmissibility, infection severity, population immunity, and the effectiveness of public health interventions. To highlight how Unity Studies protocols are being adapted and applied in national settings, WHO Headquarters, together with WHO Regional Offices, including the WHO South‑East Asia Regional Office (SEARO), hosted a global webinar. The session showcased case studies from India and the United Kingdom (UK), demonstrating innovative approaches to respiratory virus surveillance and pandemic readiness. Read moreSTRENGTHENING REGIONAL INFLUENZA SURVEILLANCE AND PREPAREDNESS: WHO SEARO HOSTS HIGH-LEVEL WEBINAR AMID RISING H5 THREATS In response to the increasing detection of avian influenza A(H5) cases in humans globally and within the WHO South‑East Asia Region, the WHO Regional Office for South‑East Asia (SEARO) convened a regional webinar on 25 July 2025 to review preparedness mechanisms, strengthen surveillance pathways, and promote timely reporting of unusual respiratory events. The virtual session brought together more than 50 participants from Ministries of Health, National Influenza Centres (NICs), National IHR Focal Points (NFPs), WHO Headquarters, WHO Country Offices across the Region, and WHO Collaborating Centres (CCs) for influenza. The webinar provided an opportunity to share situational updates, discuss surveillance gaps, and reinforce coordination mechanisms critical for early detection and rapid response to avian influenza threats. Read moreOther Key PIP Updates (July-December 2025)MEMBER STATES:Bangladesh drafted and conducted a series of Core Group Meetings in 2025 to review and update the National Pandemic Preparedness and Response Plan for Respiratory Pathogens. In addition, the country carried out Rapid Response Team (RRT) trainings on seasonal and avian influenza and other re‑emerging infectious diseases. Bangladesh also updated its epidemiological data‑training programme for physicians at sentinel surveillance sites, using a revised epidemiological data‑collection tool.Bhutan revised and updated its National Influenza Pandemic Preparedness and Response Plan (NIPPRP) in 2025 and developed a national Standard Operating Procedure (SOP) for influenza outbreak management. DPR Korea conducted a nationwide simulation exercise in July 2025 to support the update of its National Influenza Pandemic Preparedness Plan (2019). This followed a PRET‑based virtual orientation and mini‑simulation exercise held in May 2025 by SEARO and the WHO PRET Secretariat. The comprehensive exercise, conducted across central and provincial levels, assessed strengths and gaps in pandemic influenza preparedness and response. The feedback gathered has been incorporated into the revised draft plan to address identified weaknesses and strengthen overall readiness.India conducted a targeted nationwide online re‑orientation training on review and updates to the influenza portal for all State Surveillance Officers (SSOs) and relevant officials using the Integrated Health Information Platform (IHIP). The training emphasized correct marking and reporting of influenza samples as “unsubtypable” or “not subtyped” where applicable, to ensure accurate national surveillance.Maldives conducted simulation exercises in three atolls based on its existing National Pandemic Preparedness and Response Plan (NPPRP). The country plans to conduct similar exercises in three additional atolls after updating the NPPRP in 2026. In addition, Maldives conducted training on FluID and FluMart as part of a broader data‑management training package for Ministry of Health and Health Protection Agency officials, aimed at improving routine reporting to WHO platforms and the DHIS2 system.In Myanmar, technical support was provided to the National Influenza Centre (NIC) through dedicated human‑resource support (January–December 2025) to sustain data management and laboratory detection capacity for influenza and other emerging and re‑emerging respiratory viruses. This support also included strengthening genomic sequencing capacity.Nepal conducted a consultative workshop on the National Pandemic Preparedness and Response Plan (NPPRP) in July 2025. The workshop engaged key stakeholders from multiple sectors to review lessons from past pandemic responses, assess current mechanisms, and gather critical inputs for strengthening national preparedness. Key recommendations included revising the 2019 NPPRP and developing an updated Influenza Pandemic Preparedness Plan aligned with emerging risks, national priorities, and relevant international frameworks. Nepal also held a two day workshop dedicated to advancing the National Action Plan for Genomic Surveillance, aimed at reinforcing the country’s capacities for early detection and monitoring of emerging respiratory pathogens.Sri Lanka received the final report from WHO on the feasibility assessment for conducting an Influenza Burden of Disease (BoD) study in the country. The assessment, conducted from 28 April to 9 May 2025, included a desk review of existing data sources, document review, visits to sentinel surveillance sites, and key informant interviews. The study identified critical data sources required for a future BoD assessment, as well as their availability and quality. Officials from the Epidemiology Unit, the National Influenza Centre (NIC), and SARI/ILI sentinel hospitals across the country participated in the assessment.Timor Leste conducted on‑the‑job training and monitoring activities at two sentinel surveillance sites to strengthen surveillance and laboratory capacity for the detection of SARI, ILI, ARI, and other respiratory infections. REGIONAL OFFICE:SEARO conducted a Member States Consultation on the first draft of the Regional Roadmap and Strategic Action Framework for implementing WHO’s PRET‑based broad respiratory pathogen pandemic planning for 2026–2031. The consultation took place on 29–30 October 2025 during the final two days of the Regional PIP PC Annual Review and PRET Meeting in Colombo, Sri Lanka. Participants included representatives from Member States, WHO Country Offices, WHO SEARO, WHO Headquarters, partner agencies, and invited multidisciplinary technical experts. They reviewed the draft and provided detailed feedback, which has since been incorporated into a revised version. The consultation helped shape a shared regional vision for robust, PRET‑aligned pandemic preparedness, building on country‑level progress, addressing existing gaps and challenges, and aligning with global and regional health security frameworks. The publication is planned for release during the SEAR regional committee in 2026.SEARO documented the evolution of the National Influenza Pandemic Preparedness Planning process in the Region, tracing its development from its origins as a planning tool for responding to avian influenza outbreaks in 2006, through the experiences of the 2009 and 2019 pandemics, to the current status. The document outlines the way forward for respiratory pathogen pandemic planning across all 10 SEAR countries, aligning future national plans with WHO’s PRET Framework for broad respiratory pathogen pandemic preparedness.The Infectious Hazard Management (IHM) Unit has drafted the WHO South‑East Asia Regional Guidance on Influenza Prevention and Control, aligned with the Global Influenza Strategy and other regional initiatives. The draft is currently under review. Although this technical product was developed in response to a request from the Ministry of Public Health of the Democratic People’s Republic of Korea (MoPH‑DPRK), SEARO is finalizing it for use not only in DPRK but also across all Member States in the Region.The Immunization and Vaccine Development (IVD) Unit, in collaboration with WHE/SEARO, completed a regional landscape analysis on key barriers, challenges, and opportunities for the introduction of seasonal influenza vaccination in WHO South‑East Asia Regional (SEAR) countries.Additionally, the Immunization and Vaccine Development (IVD) Unit has completed a regional landscape analysis of influenza vaccine procurement systems across the WHO South‑East Asia Region (SEAR).KEY MEETINGS AND PUBLICATIONSMEETINGS:Six-month progress review of the implementation of the PIP-PC workplans in SEAR, focusing on Outputs 1 and 2 for the period January to June 2025, and held virtually across three sessions on 4, 8, and 10 July 2025. Read moreAnnual Regional Meeting (Hybrid) on Pandemic Influenza Preparedness (PIP) Partnership Contribution (PC) and WHO’s Preparedness and Resilience for Emerging Threats (PRET) Implementation in SEAR in Colombo, Sri Lanka, 27 to 30 October 2025. Read more18th Bi-regional Meeting (Virtual) of National Influenza Centres (NICs) and influenza surveillance in WHO South-East Asia and Western Pacific Regions from 9 to 11 September 2025. Read morePUBLICATIONSImplications of influenza A virus surveillance in Southeast Asian Region countries: a scoping review of approaches for the surveillance of swine influenza viruses at human-swine interfaces. Read moreAnnual South-East Asia regional meeting on operational planning for implementation of global influenza strategy and preparedness for respiratory viruses in 2025 Report on annual review meeting of implementation of pandemic influenza preparedness (PIP) partnership Contribution (PC) Fund in South-East Asia Region and the simulation exercise on PRET Status of influenza in who south-East Asia Region
New Expedition 74 Foursome Kicks off Science, Gets Used to Space
Vein scans and pharmaceutical research topped the science schedule aboard the International Space Station on Wednesday. The Expedition 74 crew rounded out the day with Dragon cargo transfers, lab familiarization activities, and life support maintenance duties.
Vanderbilt Health remembers C. Leon Partain, former chair of Radiology
Clarence Leon Partain, MD, PhD, professor emeritus of Radiology and Radiological Sciences, whose work in nuclear medicine and magnetic resonance imaging helped shape the field of academic radiology, died Jan. 28 in Brentwood, Tennessee. He was 85. After beginning his career as a nuclear engineer at Oak Ridge National Laboratory and as faculty at the University of Missouri and the University of North Carolina, Dr. Partain joined the ranks at Vanderbilt Radiology in 1980 and was promoted to professor in 1984. He later became the first Carol D. and Henry P. Pendergrass Professor of Radiology and Radiological Sciences and chair of the department (1992-2000), and subsequently the director of the Center for Imaging Research. Shortly after arriving in Nashville, Dr. Partain began to lead Vanderbilt Radiology’s nuclear medicine division. He remained in this role until he was named the department chair. Dr. Partain specialized in multiple fields, including nuclear medicine, magnetic resonance imaging and positron emission tomography. Following his time as chair, Dr. Partain shifted his focus to research and spent time working clinically with radiology’s chest imaging section. In 2015, he retired and was honored for his years of service and named as emeritus faculty. Dr. Partain also held an appointment as professor of Biomedical Engineering. A Tennessee native, Dr. Partain was born in Memphis and later graduated from high school in Clarksville. He then received his BS in nuclear engineering from the University of Tennessee, his MS and PhD in nuclear engineering from Purdue University and his MD from Washington University. He completed his residency training in diagnostic radiology and nuclear medicine at the University of North Carolina. Dr. Partain was clinically trained and certified in diagnostic radiology and nuclear radiology by the American Board of Radiology (ABR) and the American Board of Nuclear Medicine. Throughout his career, Dr. Partain contributed to the growth of Vanderbilt Radiology and received many academic and research accolades across the specialty through various associations. During his time leading the department, clinical studies increased from 180,000 to 260,000 cases per year, emerging technological imaging equipment expanded the department’s capabilities, and units for angiography and fluoroscopy were added to the tool kit. The department also expanded its footprint with outpatient imaging in Nashville, Bedford County and more. Research continued to expand with continued growth in scientific findings and millions in grant funding for radiopharmaceuticals, functional MRI, nuclear medicine, X-ray, ultrasound and more. Dr. Partain is celebrated for being instrumental in bringing the first MRI and PET/CT machines to the Medical Center. His efforts helped build Vanderbilt Radiology’s prestige in the world of academics and research both nationally and internationally. His society affiliations included the American College of Radiology, the American College of Nuclear Medicine, and the International Society of Magnetic Resonance in Medicine (ISMRM). He served as president of the Radiological Research Alliance of the Association of Academic Radiologists and has held executive roles as a member of many radiological society boards. Dr. Partain was editor-in-chief of the Journal of Magnetic Resonance Imaging from 2000 to 2013 and a member of the editorial boards of Magnetic Resonance in Medicine, Magnetic Resonance Imaging, the American Journal of Roentgenology, Academic Radiology, the Journal of Nuclear Medicine and Investigative Radiology. He has authored/co-authored/edited six textbooks, including one of the first comprehensive textbooks on MRI, “Nuclear Magnetic Resonance (NMR) Imaging.” Dr. Partain has also authored/co-authored/edited approximately 100-plus book chapters and 200-plus journal articles. In 2000, Dr. Partain received the Distinguished Service Award from the ABR. In 2014, he received the Distinguished Service Award from the ISMRM. In 2016, he received the Alumni Achievement Award from Washington University for his “contributions to advance the fields of nuclear medicine and medical imaging.” Dr. Partain served the ABR as an examiner for 20 years, the Accreditation Council for Graduate Medical Education as a member of the Nuclear Medicine Residency Review Committee, and Vanderbilt University School of Medicine in multiple capacities. A devout Baptist deacon and man of committed faith, he is survived by his wife of 62 years, Judy; children, David (Rebecca), Teri (Bland), and Amy; brother, Larry (Deb); brother-in-law, Tom (Cathy); grandchildren, Sarah (Brandon), Amy, Luke, Tucker, Alex, Ryan and Jake; cousins and a host of nieces and nephews. Vanderbilt Health is grateful to Dr. Partain for his decades of service and major contributions to clinical and research imaging.
Morgan Stanley Maintains Equal Weight on Phibro Animal Health Corporation (PAHC), Cites Margin Expansion
Phibro Animal Health Corporation (NASDAQ:PAHC) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. The seventh stock on our list of cheap pharmaceutical stocks is Phibro Animal Health Corporation (NASDAQ:PAHC). TheFly reported on February 6 that Morgan Stanley increased its price target on PAHC to $49 from $45 and maintained an Equal Weight rating. […]
Scientists Discovered An Organism That Can Become Two Different Life Forms
Knowing which genes are responsible for the transformations could help with developing antifungal treatments, and may have other pharmaceutical and industrial applications.
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, who has served as Cue Biopharma’s chief business officer (CBO) since September 2024, has been appointed chief financial and business officer (CFBO) effective February 9, 2026
Gov. Lujan Grisham named to 2026 TIME100 Health list
Lujan Grisham joins federal health care officials, pharmaceutical CEOs, scientists, researchers, actors and performers on the list.
Gov. Michelle Lujan Grisham named on the 2026 TIME100 Health list
Lujan Grisham joins federal health care officials, pharmaceutical CEOs, scientists, researchers, actors and performers on the list.
Innovation District hosts industry-informed life science skills course to support Virginia’s growing workforce needs
Throughout Virginia, the life sciences sector is gaining momentum as major pharmaceutical companies invest billions in new facilities and operations. As a result, employers need to find people who can step into laboratory and manufacturing roles right away. George Mason University's Innovation District is meeting the demand.
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department
The FDA said it would take “decisive steps” to restrict nonapproved drugs that use GLP-1 active pharmaceutical ingredients.
New recall includes nearly 23K bottles of triglycerides drug used to treat heart disease
New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness.
DHL Health Logistics Singapore Expands Capabilities to Elevate Life Science & Healthcare Logistics
DHL Group has announced the expansion of its life sciences arm—DHL Health Logistics—with the development of a €10 million Pharmaceutical Hub in Singapore. This investment bolsters regional Life Sciences and Healthcare (LSHC) infrastructure.
RFK Jr. is now a wellness guru for Republicans in Washington
Conservatives in the capital are taking up the health secretary’s advice, eating their vegetables and eschewing pharmaceuticals.
Tenacia Biopharmaceuticals and Golden Age Health Partner to Commercialize ZTALMY® for CDKL5 Deficiency Disorder in Mainland China
SHANGHAI, February 01, 2026--GAH and Tenacia announce a China commercialization partnership for ZTALMY, the first approved therapy for CDKL5 deficiency disorder.
Tanzania eyes East Africa’s pharmaceutical hub crown {Business Africa}
Tanzania is betting on local drug manufacturing to reduce imports and become East Africa’s pharmaceutical hub and we find out how Africa's private sector is fixing the supply chain to minimise the billions lost in post-harvest logistics.View on euronews
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance
NextCure Provides Business Update
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose e
Takeda inks big expansion at former Motorola Mobility campus
The pharmaceutical giant is beefing up its distribution space at Innovation Park Lake County, a win for the Chicago developer that bought it just more than a year ago.
JPM26: Chugai chases new science and name recognition from US biopharma industry
The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. | The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. Morgan Healthcare Conference in San Francisco, they’re working hard to change that while also seeking out new science to bring into their storied drug discovery operation.
3SBio Sees More Business Development Deals
Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record licensing deal the company struck with Pfizer last year. He speaks on “Bloomberg: The China Show” from San Francisco, where the JPMorgan Healthcare Conference is taking place. (Source: Bloomberg)
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance
Health Care Roundup: Market Talk
Find insight on China’s biopharmaceutical companies in the latest Market Talks covering the health care sector.
The Weight-Loss Drug Revolution—From Shots to Pills and the Science behind It All
Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Trump announces deals with nine drug companies, aiming to lower cost of medicine
In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with nine more pharmaceutical companies.
Trump secures agreements with major drugmakers to lower Medicaid prescription costs for Americans
President Donald Trump announced Friday that nine additional pharmaceutical companies joined its most-favored-nation pricing initiative.
Vertex Forward: Our animated video series
Watch the animated video series “Vertex Forward” to see the Vertex Pharmaceuticals philosophy and strategy explained.
Insmed Provides Clinical and Business Update
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Provides Clinical and Business Update
Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced today that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Brensocatib was well tolerated, with no new safety signals identified
How NIH-Funded Science Supports US Biopharmaceutical Innovation
NIH-funded research supports the foundation for industry to develop vaccines and therapies, exemplifying deep public-private R&D complementarity. As global competition intensifies, expanding NIH funding will be key to protecting American health, supporting U.S. biopharmaceutical competitiveness, and ensuring national power and security.
SPONSORED Novartis makes $23 billion investment in America's health
Ten facilities – including seven new sites – will create thousands of jobs and accelerate U.S. pharmaceutical innovation.
Holland & Knight Health Dose: December 3, 2025 | Insights
The Trump Administration finalized a trade agreement with the UK that exempts British-origin pharmaceuticals, ingredients and medical technology from Section 232 tariffs.
Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer
MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the appointment of Andreas Schuh as Chief Financial Officer (CFO), effective December 1, 2025. Andreas Schuh joins Opterion with over 20 years of leadership experience across biotech, pharma, and medical devices. He has held senior finance and operations roles at Nuclidium, Jeito, Roivant, Novartis, and Al